168 related articles for article (PubMed ID: 17508494)
1. Mechanism of action and other potential roles of an immune response modifier.
Gaspari AA
Cutis; 2007 Apr; 79(4 Suppl):36-45. PubMed ID: 17508494
[TBL] [Abstract][Full Text] [Related]
2. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
3. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod applied topically: A novel immune response modifier.
Tyring S
Skin Therapy Lett; 2001 Mar; 6(6):1-4. PubMed ID: 11298484
[TBL] [Abstract][Full Text] [Related]
5. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod applied topically: a novel immune response modifier and new class of drug.
Miller RL; Gerster JF; Owens ML; Slade HB; Tomai MA
Int J Immunopharmacol; 1999 Jan; 21(1):1-14. PubMed ID: 10411278
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod in dermatology: an overview.
Hanna E; Abadi R; Abbas O
Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373
[TBL] [Abstract][Full Text] [Related]
8. Topical imiquimod: mechanism of action and clinical applications.
Vidal D
Mini Rev Med Chem; 2006 May; 6(5):499-503. PubMed ID: 16719822
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells.
Suzuki H; Wang B; Shivji GM; Toto P; Amerio P; Tomai MA; Miller RL; Sauder DN
J Invest Dermatol; 2000 Jan; 114(1):135-41. PubMed ID: 10620129
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory and pharmacologic properties of imiquimod.
Sauder DN
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S6-11. PubMed ID: 10861101
[TBL] [Abstract][Full Text] [Related]
11. A review of the applications of imiquimod: a novel immune response modifier.
Syed TA
Expert Opin Pharmacother; 2001 May; 2(5):877-82. PubMed ID: 12219723
[TBL] [Abstract][Full Text] [Related]
12. Immune response modifiers--mode of action.
Schiller M; Metze D; Luger TA; Grabbe S; Gunzer M
Exp Dermatol; 2006 May; 15(5):331-41. PubMed ID: 16630072
[TBL] [Abstract][Full Text] [Related]
13. Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.
Badavanis G; Pasmatzi E; Monastirli A; Georgiou S; Tsambaos D
Acta Dermatovenerol Croat; 2017 Jul; 25(2):164-166. PubMed ID: 28871935
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
[TBL] [Abstract][Full Text] [Related]
15. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463.
Imbertson LM; Beaurline JM; Couture AM; Gibson SJ; Smith RM; Miller RL; Reiter MJ; Wagner TL; Tomai MA
J Invest Dermatol; 1998 May; 110(5):734-9. PubMed ID: 9579537
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 7 agonists and skin.
Novak N; Yu CF; Bieber T; Allam JP
Drug News Perspect; 2008 Apr; 21(3):158-65. PubMed ID: 18560614
[TBL] [Abstract][Full Text] [Related]
17. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion.
Schön MP; Schön M; Klotz KN
J Invest Dermatol; 2006 Jun; 126(6):1338-47. PubMed ID: 16575388
[TBL] [Abstract][Full Text] [Related]
18. Current and potential uses of imiquimod.
Chang YC; Madkan V; Cook-Norris R; Sra K; Tyring S
South Med J; 2005 Sep; 98(9):914-20. PubMed ID: 16217984
[TBL] [Abstract][Full Text] [Related]
19. The antiviral activity of Toll-like receptor 7 and 7/8 agonists.
Miller RL; Meng TC; Tomai MA
Drug News Perspect; 2008 Mar; 21(2):69-87. PubMed ID: 18389099
[TBL] [Abstract][Full Text] [Related]
20. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
